Vaccine-like nanomedicine for cancer immunotherapy

Y Yi, M Yu, W Li, D Zhu, L Mei, M Ou - Journal of Controlled Release, 2023 - Elsevier
The successful clinical application of immune checkpoint blockade (ICB) and chimeric
antigen receptor T cells (CAR-T) therapeutics has attracted extensive attention to …

Stress-induced Epstein-Barr virus reactivation

DG Sausen, MS Bhutta, ES Gallo, H Dahari… - Biomolecules, 2021 - mdpi.com
Epstein-Barr virus (EBV) is typically found in a latent, asymptomatic state in
immunocompetent individuals. Perturbations of the host immune system can stimulate viral …

Urgency and necessity of Epstein-Barr virus prophylactic vaccines

L Zhong, C Krummenacher, W Zhang, J Hong, Q Feng… - npj Vaccines, 2022 - nature.com
Abstract Epstein-Barr virus (EBV), a γ-herpesvirus, is the first identified oncogenic virus,
which establishes permanent infection in humans. EBV causes infectious mononucleosis …

A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV

C Sun, YF Kang, XY Fang, YN Liu, GL Bu, AJ Wang… - Cell Host & Microbe, 2023 - cell.com
Epstein-Barr virus (EBV) is a global public health concern, as it is known to cause multiple
diseases while also being etiologically associated with a wide range of epithelial and …

Vaccination strategies based on bacterial self-assembling proteins as antigen delivery nanoscaffolds

F Lamontagne, V Khatri, P St-Louis, S Bourgault… - Vaccines, 2022 - mdpi.com
Vaccination has saved billions of human lives and has considerably reduced the economic
burden associated with pandemic and endemic infectious diseases. Notwithstanding major …

GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection

C Liu, S Li, M Qiao, C Zeng, X Liu, Y Tang - Archives of Virology, 2024 - Springer
Epstein‒Barr virus (EBV) is a double-stranded DNA virus belonging to the family
Orthoherpesviridae that is associated with the development of various tumors, such as …

Main targets of interest for the development of a prophylactic or therapeutic Epstein-Barr virus vaccine

V Jean-Pierre, J Lupo, M Buisson, P Morand… - Frontiers in …, 2021 - frontiersin.org
Epstein-Barr virus (EBV) is one of the most widespread viruses in the world; more than 90%
of the planet's adult population is infected. Symptomatic primary infection by this …

A self-assembled nanoparticle vaccine based on pseudorabies virus glycoprotein D induces potent protective immunity against pseudorabies virus infection

X Ren, N Cao, L Tian, W Liu, H Zhu, Z Rong… - Veterinary …, 2023 - Elsevier
Pseudorabies virus (PRV) mainly causes pseudorabies (PR) or Aujeszky's disease in pigs
and can infect humans, raising public health concerns about zoonotic and interspecies …

Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice

GM Escalante, IG Reidel, LZ Mutsvunguma… - Frontiers in …, 2024 - frontiersin.org
Introduction Epstein-Barr virus (EBV) is an oncogenic human herpesvirus associated with~
350,000 cases of lymphoid and epithelial malignancies every year, and is etiologically …

Improving cross-protection against influenza virus in mice using a nanoparticle vaccine of mini-HA

H Zhu, X Li, X Ren, H Chen, P Qian - Vaccine, 2022 - Elsevier
This study aimed to investigate the protective effect of mini-hemagglutinin (mini-HA) proteins
expressed on lumazine synthase (LS) nanoparticles against influenza. Soluble mini-HA …